) posted a 16.7% rise in adjusted earnings to 14 cents per share
for the second quarter of 2014 from 12 cents per share in the same
quarter of 2013. With this, earnings per share exceeded the Zacks
Consensus Estimate of 12 cents per share.
The company's adjusted earnings in the reported quarter exclude
amortization of acquired intangible assets, costs associated with
legal proceedings and restructuring costs.
On a reported basis, net earnings augmented 27.9% to $4.7 million
from $3.7 million in the second quarter of 2013. Reported net
earnings per share increased 22.2% to 11 cents from 9 cents posted
a year ago.
Revenues edged up 2.5% to $55.6 million in the second quarter,
however, it fell shy of the Zacks Consensus Estimate of $57.0
million. The rise in revenues was driven by growth across systems,
consumables and royalty revenues.
Following the earnings release, shares of Luminex climbed 8.1% to
close at $19.00 yesterday.
Expenses and Margins
Gross profit inched up 0.2% to $38.1 million in the reported
quarter. However, gross margin slid 150 basis points (bps) to 68.6%
from 70.1% in the year-ago quarter.
Research and development expenses fell 4.1% to $11.3 million,
primarily due to savings and material spending as a part of the
shift in Luminex's ARIES system development from alphas to betas.
Selling, general and administrative expenses went up 3.8% to $21.0
million in the quarter. While general and administrative costs were
essentially flat year over year, sales and marketing expenses grew
modestly as a result of some incremental resource investments in
the company's direct sales activities.
Adjusted operating income for the quarter increased 5.4% to $7.1
million from $6.7 million in the year-ago quarter while adjusted
operating margin rose 40 bps to 12.7% from 12.3% in the second
quarter of 2013.
Technology and strategic partnerships
(TSP) stood at $33.4 million, up 7.2% from $31.1 million in the
second quarter of 2013. The upside was driven by growth across all
major components of the business - consumable sales, system sales,
royalty and services.
Operating income from this segment escalated 34.8% to $8.6 million
while operating margin expanded 530 bps to 25.8% from 20.5% a year
Assays and related products
(ARP) revenues declined 3.9% to $22.2 million from $23.1 million in
the year-ago quarter. The decline was primarily attributable to the
bankruptcy of a previous customer and irregularity in the timing of
other assay revenue components.
Operating loss at this segment widened 184.6% to $3.9 million while
operating (loss) margin expanded significantly by 1,150 bps to
17.3% from 5.8% in the second quarter of 2013.
Segment Revenues in Detail
went up 7.5% to $12.6 million in the quarter driven by higher
purchase volumes from Luminex's largest customers. Bulk purchases
by 14 customers during the quarter comprised 77% of total
consumable revenues, amounting to $9.7 million.
increased 8.6% to $8.3 million, boosted by a system mix with a
higher concentration of LX and FLEXMAP 3D systems instead of MAGPIX
systems in the prior-year quarter. The upside was modestly offset
by a reduction in sales of automated punching systems from
Luminex's Australian subsidiary that resulted from the
restructuring announced in late 2013.
revenues spiked 10.5% to $9.5 million in the quarter buoyed by
higher end-user sales compared to the prior-year period, partially
mitigated by a fall in minimal royalty and one-time payments.
revenues declined 8.4% to $19.9 million in the second quarter of
2014. Within total assay sales, infectious disease sales comprised
67% while genetic testing sales accounted for 33% compared with 68%
and 32%, respectively, in the second quarter of 2013.
Revenue from all
sources climbed 15.7% to $5.3 million in the second quarter.
Luminex had cash and cash equivalents of $86.7 million as of Jun
30, 2014, up 27.7% from $67.9 million at the end of 2013. As of Jun
30, 2014, Luminex had no long-term debt as compared with $1.7
million as of Dec 31, 2013.
In the first half of 2014, cash flow from operations totaled $21.7
million, up significantly by 240.7% from $6.4 million in the
comparable year-ago period. Capital expenditures stood at $6.2
million, down 24.1% from the first half of 2013.
For 2014, Luminex reaffirmed its revenues guidance in the range of
$225 to $240 million, reflecting an increase of 5 to 12% over 2013.
The Zacks Consensus Estimate of $230 million lies within the guided
Luminex presently carries a Zacks Rank #3 (Hold). Better-ranked
stocks in the medical instruments industry include Accuray
), RTI Surgical Inc. (
) and Heartware International Inc. (
). While Accuray and RTI Surgical sport a Zacks Rank #1 (Strong
Buy), Heartware International carries a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
LUMINEX CORP (LMNX): Free Stock Analysis Report
ACCURAY INC (ARAY): Free Stock Analysis Report
HEARTWARE INTL (HTWR): Free Stock Analysis
RTI SURGICAL (RTIX): Free Stock Analysis Report
To read this article on Zacks.com click here.